Planta Med 2019; 85(18): 1407
DOI: 10.1055/s-0039-3399684
Abstracts of Short Lectures
Short Lectures Monday, September 02, 2019
Short Lectures A: Biological and Pharmacological Activities of Natural Products
© Georg Thieme Verlag KG Stuttgart · New York

Protective effect of Plumericin in inflammatory bowel disease: regulation of inflammatory and oxidative stress response in vitro and in vivo

SF Rapa
1   University of Salerno, Department of Pharmacy, School of Pharmacy, Via Giovanni Paolo II 132, 84084, Fisciano, SA, Italy
,
B Waltenberger
2   Leopold-Franzens University of Innsbruck, Institute of Pharmacy, Member of the Center for Molecular Biosciences Innsbruck, Austria
,
R Di Paola
3   University of Messina, Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, Messina, Italy
,
G Autore
1   University of Salerno, Department of Pharmacy, School of Pharmacy, Via Giovanni Paolo II 132, 84084, Fisciano, SA, Italy
,
S Cuzzocrea
3   University of Messina, Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, Messina, Italy
,
H Stuppner
2   Leopold-Franzens University of Innsbruck, Institute of Pharmacy, Member of the Center for Molecular Biosciences Innsbruck, Austria
,
S Marzocco
1   University of Salerno, Department of Pharmacy, School of Pharmacy, Via Giovanni Paolo II 132, 84084, Fisciano, SA, Italy
› Author Affiliations
Further Information

Publication History

Publication Date:
20 December 2019 (online)

Also available at
 

Inflammatory bowel diseases (IBDs) are characterized by chronic relapsing intestinal inflammation. Although IBDs etiology remains unknown, the mechanisms of inflammation and oxidative stress as well as dysbiotic conditions and aberrations in the epithelial barrier are recognized as involved in the pathogenesis of these diseases [1]. Conventional therapy in IBDs uses anti-inflammatory and immunosuppressive corticosteroids, as well as biological drugs, however, the low remission rate and the severe side effects of these therapies are not satisfactory for IBDs pharmacological treatment. Thus, there is a great need for new drugs with anti-inflammatory and anti-oxidant activities.

In this study we evaluated the effect of Plumericin, one of the main bioactive components extracted from the bark of Himatanthus sucuuba (Woodson) on intestinal inflammation, both in vitro, on rat intestinal epithelial cells (IEC-6), and in vivo, in an experimental model of DNBS-induced colitis.

Our results indicated that Plumericin significantly reduces pro-inflammatory factors with a pivotal role in IBDs, such as tumor necrosis factor-α (TNF-α) levels, cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS) expression and nitrotyrosine formation. Plumericin was also able to inhibit nuclear factor-kB (NF-kB) activation and to reduce reactive oxygen species (ROS) release. Moreover, Plumericin activates the nuclear factor erythroid-derived 2 (Nrf2) anti-oxidant pathway and inhibited inflammasome activation in IEC-6. The anti-inflammatory and antioxidant effects observed in vitro, associated with a reduced intestinal macroscopic damage, were confirmed in vivo in DNBS-induced colitis in rat.

Plumericin shows anti-inflammatory and antioxidant activities at intestinal level and therefore, could be a promising agent the treatment of IBDs.

 

  • References

  • 1 Naga K.R, Ghattamanenia S K, Panchal LB. Nutraceuticals in rodent models as potential treatments for human Inflammatory Bowel Disease. Pharmacol Res June 2018; 132: 99-107.
    CrossrefPubMedGoogle Scholar